vs

Side-by-side financial comparison of Fluent, Inc. (FLNT) and MESA LABORATORIES INC (MLAB). Click either name above to swap in a different company.

MESA LABORATORIES INC is the larger business by last-quarter revenue ($65.1M vs $61.8M, roughly 1.1× Fluent, Inc.). MESA LABORATORIES INC runs the higher net margin — 5.6% vs -6.7%, a 12.2% gap on every dollar of revenue. On growth, MESA LABORATORIES INC posted the faster year-over-year revenue change (3.6% vs -5.5%). Over the past eight quarters, MESA LABORATORIES INC's revenue compounded faster (5.1% CAGR vs -3.2%).

THG Fluently, formerly Language Connect, is a translation and language localisation service provided by THG Ingenuity. It provides a range of language services, including translation, interpreting, localisation, voice-overs, transcription, and multilingual search engine optimization.

Mesa Laboratories Inc. develops, manufactures and sells professional quality control, calibration and monitoring instruments as well as related supporting services. Its core offerings cater to healthcare, pharmaceutical, food and beverage, industrial hygiene and environmental testing markets, helping global clients meet regulatory compliance and operational safety requirements.

FLNT vs MLAB — Head-to-Head

Bigger by revenue
MLAB
MLAB
1.1× larger
MLAB
$65.1M
$61.8M
FLNT
Growing faster (revenue YoY)
MLAB
MLAB
+9.1% gap
MLAB
3.6%
-5.5%
FLNT
Higher net margin
MLAB
MLAB
12.2% more per $
MLAB
5.6%
-6.7%
FLNT
Faster 2-yr revenue CAGR
MLAB
MLAB
Annualised
MLAB
5.1%
-3.2%
FLNT

Income Statement — Q4 FY2025 vs Q3 FY2026

Metric
FLNT
FLNT
MLAB
MLAB
Revenue
$61.8M
$65.1M
Net Profit
$-4.1M
$3.6M
Gross Margin
64.2%
Operating Margin
0.3%
12.2%
Net Margin
-6.7%
5.6%
Revenue YoY
-5.5%
3.6%
Net Profit YoY
-20.1%
316.6%
EPS (diluted)
$-0.09
$0.65

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
FLNT
FLNT
MLAB
MLAB
Q4 25
$61.8M
$65.1M
Q3 25
$47.0M
$60.7M
Q2 25
$44.7M
$59.5M
Q1 25
$55.2M
$62.1M
Q4 24
$65.4M
$62.8M
Q3 24
$64.5M
$57.8M
Q2 24
$58.7M
$58.2M
Q1 24
$66.0M
$58.9M
Net Profit
FLNT
FLNT
MLAB
MLAB
Q4 25
$-4.1M
$3.6M
Q3 25
$-7.6M
$2.5M
Q2 25
$-7.2M
$4.7M
Q1 25
$-8.3M
$-7.1M
Q4 24
$-3.4M
$-1.7M
Q3 24
$-7.9M
$3.4M
Q2 24
$-11.6M
$3.4M
Q1 24
$-6.3M
$-254.6M
Gross Margin
FLNT
FLNT
MLAB
MLAB
Q4 25
64.2%
Q3 25
61.5%
Q2 25
62.0%
Q1 25
61.8%
Q4 24
63.3%
Q3 24
61.3%
Q2 24
64.0%
Q1 24
62.1%
Operating Margin
FLNT
FLNT
MLAB
MLAB
Q4 25
0.3%
12.2%
Q3 25
-13.4%
7.8%
Q2 25
-15.9%
5.1%
Q1 25
-12.8%
2.4%
Q4 24
-8.3%
9.2%
Q3 24
-6.0%
6.1%
Q2 24
-17.7%
9.6%
Q1 24
-6.0%
-460.6%
Net Margin
FLNT
FLNT
MLAB
MLAB
Q4 25
-6.7%
5.6%
Q3 25
-16.1%
4.1%
Q2 25
-16.2%
8.0%
Q1 25
-15.0%
-11.4%
Q4 24
-5.2%
-2.7%
Q3 24
-12.3%
5.9%
Q2 24
-19.8%
5.8%
Q1 24
-9.5%
-432.2%
EPS (diluted)
FLNT
FLNT
MLAB
MLAB
Q4 25
$-0.09
$0.65
Q3 25
$-0.27
$0.45
Q2 25
$-0.30
$0.85
Q1 25
$-0.39
$-1.30
Q4 24
$-0.12
$-0.31
Q3 24
$-0.48
$0.63
Q2 24
$-0.75
$0.62
Q1 24
$-0.45
$-47.26

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
FLNT
FLNT
MLAB
MLAB
Cash + ST InvestmentsLiquidity on hand
$12.9M
$29.0M
Total DebtLower is stronger
$34.6M
$68.4M
Stockholders' EquityBook value
$18.2M
$186.7M
Total Assets
$89.1M
$434.8M
Debt / EquityLower = less leverage
1.90×
0.37×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
FLNT
FLNT
MLAB
MLAB
Q4 25
$12.9M
$29.0M
Q3 25
$9.2M
$20.4M
Q2 25
$4.9M
$21.3M
Q1 25
$4.8M
$27.3M
Q4 24
$9.4M
$27.3M
Q3 24
$6.6M
$24.3M
Q2 24
$5.0M
$28.5M
Q1 24
$11.7M
$28.2M
Total Debt
FLNT
FLNT
MLAB
MLAB
Q4 25
$34.6M
$68.4M
Q3 25
$26.0M
$69.4M
Q2 25
$23.2M
$70.3M
Q1 25
$25.6M
$71.3M
Q4 24
$35.6M
$72.2M
Q3 24
$37.9M
$73.1M
Q2 24
$33.3M
$74.1M
Q1 24
$31.0M
Stockholders' Equity
FLNT
FLNT
MLAB
MLAB
Q4 25
$18.2M
$186.7M
Q3 25
$21.6M
$178.5M
Q2 25
$19.1M
$172.5M
Q1 25
$22.0M
$159.8M
Q4 24
$25.0M
$155.2M
Q3 24
$20.0M
$161.5M
Q2 24
$27.5M
$150.7M
Q1 24
$28.7M
$145.4M
Total Assets
FLNT
FLNT
MLAB
MLAB
Q4 25
$89.1M
$434.8M
Q3 25
$76.1M
$430.4M
Q2 25
$74.5M
$435.7M
Q1 25
$77.5M
$433.3M
Q4 24
$93.6M
$433.3M
Q3 24
$77.5M
$454.1M
Q2 24
$98.5M
$440.4M
Q1 24
$103.6M
$446.8M
Debt / Equity
FLNT
FLNT
MLAB
MLAB
Q4 25
1.90×
0.37×
Q3 25
1.21×
0.39×
Q2 25
1.21×
0.41×
Q1 25
1.16×
0.45×
Q4 24
1.43×
0.47×
Q3 24
1.90×
0.45×
Q2 24
1.21×
0.49×
Q1 24
1.08×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
FLNT
FLNT
MLAB
MLAB
Operating Cash FlowLast quarter
$2.8M
$18.8M
Free Cash FlowOCF − Capex
$18.0M
FCF MarginFCF / Revenue
27.7%
Capex IntensityCapex / Revenue
1.1%
Cash ConversionOCF / Net Profit
5.17×
TTM Free Cash FlowTrailing 4 quarters
$37.9M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
FLNT
FLNT
MLAB
MLAB
Q4 25
$2.8M
$18.8M
Q3 25
$-7.3M
$8.2M
Q2 25
$935.0K
$1.9M
Q1 25
$2.1M
$12.7M
Q4 24
$-2.1M
$18.1M
Q3 24
$1.2M
$5.3M
Q2 24
$-13.1M
$10.7M
Q1 24
$-132.0K
$12.9M
Free Cash Flow
FLNT
FLNT
MLAB
MLAB
Q4 25
$18.0M
Q3 25
$-7.3M
$7.1M
Q2 25
$884.0K
Q1 25
$11.9M
Q4 24
$17.3M
Q3 24
$1.2M
$3.5M
Q2 24
$9.9M
Q1 24
$12.3M
FCF Margin
FLNT
FLNT
MLAB
MLAB
Q4 25
27.7%
Q3 25
-15.6%
11.7%
Q2 25
1.5%
Q1 25
19.2%
Q4 24
27.6%
Q3 24
1.9%
6.0%
Q2 24
16.9%
Q1 24
21.0%
Capex Intensity
FLNT
FLNT
MLAB
MLAB
Q4 25
1.1%
Q3 25
0.0%
1.8%
Q2 25
1.7%
Q1 25
1.2%
Q4 24
1.3%
Q3 24
0.0%
3.1%
Q2 24
1.5%
Q1 24
0.9%
Cash Conversion
FLNT
FLNT
MLAB
MLAB
Q4 25
5.17×
Q3 25
3.32×
Q2 25
0.40×
Q1 25
Q4 24
Q3 24
1.54×
Q2 24
3.17×
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

FLNT
FLNT

Commerce Media Solutions$34.7M56%
Owned And Operated$21.3M34%
Call Solutions$3.8M6%
Ad Parlor$2.0M3%

MLAB
MLAB

Sterilization And Disinfection Control$24.9M38%
Biopharmaceutical Development$14.4M22%
Other$14.1M22%
Clinical Genomics$11.8M18%

Related Comparisons